Biocon shares gained 2.6 percent to hit a record high of Rs 1,123 after the US health regulator USFDA has accepted pharma major Mylan's biologics licence application (BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim.
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylan‘s biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the presentation of data from the HERITAGE study at ...
In February this year, Gilead appointed Mylan as its exclusive distributor of Sovaldi in India. Mylan president Rajiv Malik said they have a history of partnering with Gilead to tackle key public health issues in India and around the world, beginning with expanding access to high quality and affordable HIV/AIDS antiretrovirals.
Rajeev Malik of CLSA told CNBC-TV18 believes India is still facing the risk of a downgrade.
Speaking to CNBC-TV18 Rajiv Malik from CLSA said headline inflation level would head higher. He rubbished claims that the UPA government has made sweeping reforms and chose to credit them for taking decision that were long overdue.
Rajiv Malik, senior economist, CLSA too feels that 25 bps hike by the central bank was not surprising. In fact, while speaking to CNBC-TV18, he mentioned that the RBI has done the right thing to still sound hawkish.
The Reserve Bank of India is meeting today to review its mid-term monetary policy. Most analysts on the street including Rajeev Malik, senior economist at CLSA, feel that the RBI will raise interest rate at least by 25 basis points.